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Abstract. Cognitive impairment is common in Parkinson’s disease (PD), and many patients will eventually develop a dementia,
which has a devastating impact on the patient and their family. As such, there has been much interest in identifying a prodromal
state to inform prognosis and facilitate earlier management, similar to the concept of ‘MCI’ in the Alzheimer’s field. However,
grouping the early cognitive deficits of PD together as ‘PD-MCI’ may not be the best way forward as it implies a single
aetiological basis with one clinical consequence. In this review, we argue that cognitive deficits in PD arise from a number
of different pathological pathways, only some of which herald a dementing process. This has important implications both for
treatment of individual patients, and for the design of future disease-modifying therapy trials.
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INTRODUCTION
Parkinson’s disease (PD), whilst classically a motor
disorder, has long been recognised to have many non-
motor features which map on to the pathology that
is now known to extend outside of the dopaminergic
cells of the substantia nigra and involve many differ-
ent neuronal populations [1]. These non-motor features
encompass a range of symptoms and signs, but per-
haps the one most feared by patients and their families
is the dementia of PD that can affect up to 50% of
patients 10 years after diagnosis [2] and over 80% by
20 years [3]. As such many see the dementia of PD
(PDD) as the inevitable consequence of having the dis-
ease for a long time, especially in the context of an
aged CNS. If true then it must be possible to pick up
the early features of this disease process ahead of the
overt dementia, in much the same way as has been tried
in Alzheimer’s Disease (AD). In the Alzheimer’s field,
this prodromal state has been termed Mild Cognitive
Impairment (MCI), often considered as an intermediate
state between normal aging and dementia. However,
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whilst a useful concept, this is only a syndromic def-
inition which does not necessarily imply a particular
pathology. It is not always a reliable marker of incipi-
ent AD, with some patients never progressing or even
improving [4]. As such the importance and value of
this diagnostic entity has been questioned [5].
Nevertheless the principle of what MCI is trying to
capture is a useful one, and the concept has of late
been applied to PD, [6] even though concerns about
doing this given the problems with its adoption in AD
have been voiced [7]. Thus the question arises - can
we use the term PD-MCI to capture a prodromal PDD
state? This of course brings with it another question,
what defines the MCI of PD and does it have a single
aetiological basis and thus one clinical consequence?
In this review we will argue that cognitive deficits in
PD are common and arise from a number of different
pathological pathways, only some of which herald a
dementing process.
WHAT ARE THE COGNITIVE DEFICITS
OF PD?
There is a long history of studies looking at the
cognitive deficits of PD which have largely revolved
around executive deficits that link to frontostriatal
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pathways, given that the core pathology in PD tar-
gets the basal ganglia circuitry [8]. These deficits
include problems with planning and working memory-
namely the capacity to store information online to solve
ongoing cognitive problems. These deficits have been
shown to occur at different stages of disease and to
respond positively or negatively to dopaminergic ther-
apies, [9] which has made the literature in this area
complicated. However, the basis of these deficits seems
to lie in dysfunctional dopaminergic networks which
vary as a function of disease stage, drug therapy and
the genotypic makeup of the patient (see below).
Another common cognitive deficit in PD is mem-
ory impairment, including problems with free recall
[10] and learning new information [11]. These deficits
can be hard to disentangle as in some instances the
problem may relate more to issues of attention and
impairment of executive search and retrieval strate-
gies than to memory impairment per se, [12] whilst
in others the memory deficits may relate to concurrent
Alzheimer’s-type pathology, which may occur in up to
50% of patients with PD dementia [13].
Finally visuospatial deficits can occur, [14] and
indeed can dominate the cognitive problems in patients
with Dementia with Lewy bodies (DLB) and PDD.
These deficits are measurable in tasks involving copy-
ing complex figures and visual orientation and are
likely to contribute to the occurrence of visual halluci-
nations and misrepresentations [15]. These problems
probably reflect cortical Lewy body pathology and
cholinergic deficits [16] but may also be exacerbated
by drug therapies and other problems such as infections
and metabolic disturbances.
Thus patients with PD may present with no cogni-
tive deficits, deficits in a single cognitive domain or
deficits in multiple cognitive domains. This nomen-
clature of single versus multi-domain MCI has been
adopted by many to help describe the cognitive prob-
lem being reported [6, 17]. However we would posit
that the domain affected may be more informative in
terms of predicting progression than the number of
domains affected.
WHAT CAN CAUSE THE COGNITIVE
DEFICITS IN PD?
Patients with PD may do badly on tests of cognition
for the following reasons:
• the intrinsic pathology of Parkinson’s disease –
namely the Lewy body pathology and cholinergic
deficits;
• non PD pathology such as coexistent AD;
• drug therapies being taken for their PD and/or
other conditions;
• depression or a major affective disorder;
• an acute confusional state secondary to another
cause such as infection or metabolic disturbance;
• fatigue and somnolence making it hard for them
to engage with cognitive tasks;
• low baseline cognitive function due to low educa-
tional attainment.
The recently proposed MDS PD-MCI criteria [6]
attempt to exclude poor cognitive performance due
to co-morbid conditions or severe affective or psy-
chiatric disturbance, but nonetheless it is clear that
cognitive deficits in PD often have a complex multi-
factorial basis. In addition it is debatable what actually
constitutes a cognitive deficit- Is it when the patient
performs, 1 or 1.5 or 2 standard deviations below their
age/sex matched controls? Is it when they have a cogni-
tive impairment that begins to impact on their function
and activities of daily living?
Therefore it is not straightforward to say whether a
patient actually has a cognitive deficit nor what this is
due to. Longitudinal studies are crucial in terms of bet-
ter describing these deficits and their significance for
long-term prognosis. However, historically such stud-
ies have failed to give a consistent picture, implicating a
number of different neuropsychological deficits as pre-
dictors of dementia in PD, including executive deficits,
[18–20] poor verbal fluency, [20, 21] visuospatial dys-
function, [20] and language and memory deficits [19,
22]. This inconsistency is likely to relate to impor-
tant methodological differences between these studies
including the nature of the cohorts (hospital versus
community-based), disease stage of patients included,
and the choice of neuropsychological assessments.
In our own CamPaIGN study, we attempted to over-
come some of these problems with previous studies,
by describing the evolution of cognitive problems from
the time of diagnosis in a community-based cohort
which was generalizable to the PD population as a
whole.
Our original CamPaIGN study set about collecting
all incident cases of PD over a 2 year period (Decem-
ber 2000–2002) in the county of Cambridgeshire in
the UK using UKPDS Brain Bank criteria for diagno-
sis [23]. The cohort was a population-representative
sample collected from the community and then fol-
lowed up over time, with ongoing assessments until
the present day. The patients could not have a demen-
tia on entering the study (otherwise they would have
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been defined as having DLB). They were examined
with a detailed neuropsychological battery as well as a
range of other standardised motor, affective and func-
tional assessments. These assessments have been done
every 2 years and the natural history of disease plotted,
including conversion to dementia. In addition geno-
typing studies have been done on these patients to try
and identify genetic factors that link to their cognitive
course [2]. Using this approach we have described 2
cognitive syndromes in PD (see Fig. 1): [24]
(i) A frontostriatal executive syndrome that relates
to changes in the dopaminergic networks and
which varies as a function of disease stage,
dopaminergic medication and COMT genotype.
The deficits so identified can best be modelled
using an inverted U-shaped relationship in which
working memory or similar cognitive function
has an optimal dopamine level. Too much or too
little causes impairments in task performance. As
such these deficits have a complex relationship to
PD, but a simple one to PDD in that they are not
predictive or associated with its development.
(ii) In contrast, the second type of cognitive syn-
drome does evolve into dementia, and is
characterised in its early stages by visuospatial
deficits (such as difficulty copying the inter-
locking pentagons found in the MMSE) as well
as temporal lobe-based deficits (such as poor
semantic, but not phonemic, fluency). These
patients tend to be older at presentation and are
more likely to possess the MAPT (tau) H1/H1
genotype and/or a heterozygote GBA mutation
[25]. The underlying aetiology of this syndrome
is likely to involve Lewy body pathology in pos-
terior cortical regions, as well as cholinergic
deficits in these areas [26].
Although as yet, not all aspects of this work have
been fully replicated, there is nonetheless an emerging
consensus from clinical [27, 28] and genetic studies
[29] that the basic principles are true. Furthermore,
studies using a range of imaging modalities includ-
ing structural MRI [30], SPECT [31] and FDG-PET
[32] to investigate PD patients with cognitive impair-
ment support the hypothesis that pathological changes
in posterior cortical regions are associated with pro-
gression to dementia in PD.
The existence of these two distinct syndromes may
help us better understand the heterogeneity of cog-
nitive deficits in PD and their prognostic relevance.
However whilst helpful, this is not the whole story as
some cognitive aspects of PD have alternate aetiologies
such as problems with impulsivity and compulsivity
which involve noradrenergic [33] and serotoninergic
dysfunction [34] as well as dopaminergic dysfunc-
tion. In addition the amnesic deficits are hard to tie
down in terms of specific network problems, and are
unlikely to be due solely to AD pathology, although
this may account for memory deficits in some PD
patients, [13] particularly given that the average age
of PD diagnosis is around 70 years in population-
based cohorts [2]. In keeping with this, a decrease in
amyloid-beta 1-42 in CSF, which is well demonstrated
in Alzheimer’s disease, has also been shown to predict
more rapid cognitive decline in PD [35, 36]. Neverthe-
less the important point is that the MCI covers a range
of deficits, with a variety of aetiologies and varying
prognostic significance, and this in turn has important
therapeutic implications.
HOW CAN WE TREAT THE COGNITIVE
DEFICITS OF PD?
The above discussion enables one to predict how
to approach the treatment of the cognitive deficits of
PD, although therapeutic options at present are very
limited. Typical strategies may include:
• manipulation of the dopaminergic agents being
used for the motor aspects of the disorder, which
may be contributing to executive dysfunction, and
exacerbating hallucinations in the later stages of
the disease;
• the use of cholinergic agents to boost the failing
cholinergic system which is likely to be con-
tributing to the ‘posterior cortical’ dementing
syndrome;
• the treatment of any other disease feature that
could be contributing to poor cognitive perfor-
mance such as fatigue, somnolence or depression.
In all patients with cognitive impairment, a stan-
dard approach involves first looking at the drugs and
or any other co-existent illnesses that may be driving
it – e.g. a urinary tract infection or metabolic dis-
turbance. In many cases the dopaminergic drugs are
contributory: in the case of executive deficits they may
be contributing to a hyperdopaminergic state which
is detrimental to executive performance, [37] whilst
in the more posterior cortical presentation of incip-
ient PD dementia they may be aggravating the visual
hallucinations and behavioural problems through stim-
ulation of the dopaminergic network at this site. In view
of this, dopaminergic drugs are often manipulated,
654 R.A. Barker and C.H. Williams-Gray / Mild Cognitive Impairment and PD
Fig. 1. Schematic representation of 2 distinct cognitive syndromes in early PD, which differ in terms of their underlying aetiological basis, and
prognosis. (Adapted from Williams-Gray et al., [24]).
removing dopamine agonists and reducing the dose
of L-dopa, although with this comes a worsening of
their motor state. As such other agents are needed such
as cholinesterase inhibitors for patients with incipient
or early PDD [38]. Memantine, an NMDA receptor
antagonist, has also shown some early promise in
small randomised controlled trials in PDD [39]. In
the case of the patients with more prominent exec-
utive deficits, there has been interest in agents that
may have an alerting capacity such as modafanil,
[40] as well as drugs targeting the noradrenergic sys-
tem such as atomoxetine [33]. Another therapeutic
strategy which is gaining an evidence base for early
cognitive deficits in PD is cognitive training, [41, 42]
although it remains to be seen whether demonstrated
improvements on neuropsychological tests translate
into real-world improvements in cognitive function.
Finally the significance of these cognitive syn-
dromes is not restricted to their symptomatic treatment
but may also facilitate more successful disease-
modifying therapy trials. For example, our work
indicates that newly-diagnosed PD patients with the
H1/H1 MAPT genotype who are unable to accurately
copy interlocking pentagons and cannot generate a list
of at least 20 animals in 90 seconds in a semantic
fluency task are at much higher risk of developing
dementia within the next 5 years (PPV 58%) than
patients exhibiting none of these risk factors (PPV 0%)
[2]. If you therefore enriched for individuals within
the former group and gave them a disease-modifying
therapy, one would have a very good chance of see-
ing a significant effect over 5 years of follow-up using
dementia as the primary end-point. In reality, most
studies recruit individuals in the latter group with no
demonstrable cognitive impairment at baseline, and in
this group, there is no chance of seeing any effect of
treatment on dementia incidence, and measuring dis-
ease progression using standard motor measures is
almost impossible given the confounding effects of
symptomatic therapy. Thus better understanding early
cognitive deficits of PD and their significance may have
an important impact on the future of disease-modifying
therapy trials.
CONCLUSION
In this review, we have highlighted the fact that
cognitive impairments in PD are common, but these
cognitive deficits represent a range of pathologies and
each carries a different significance for patients, as well
as therapeutically. Thus encompassing all these deficits
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under a single ‘PD-MCI’ syndrome may not be appro-
priate. It is now critical for the field to better define the
causes of the different types of cognitive deficits in PD,
and how they relate to each other and to the develop-
ment of dementia. By so doing, we will avoid some of
the problems that have dogged the field of MCI in AD,
as well as enabling more productive trials of disease
modifying therapies that could ultimately slow down
the development of the most feared complication of
PD, namely the dementia associated with it.
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